Grace Therapeutics (GRCE) Stock Price, News & Analysis

Company Overview

Grace Therapeutics, Inc. (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.

The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions. Through in-house capabilities and strategic partnerships with academic institutions and contract research organizations, Grace Therapeutics advances its candidates from target identification through lead optimization with the goal of accelerating entry into formal regulatory pathways.

Based in the United States, Grace Therapeutics serves a global patient community by collaborating with development partners worldwide. The management team combines experience in drug discovery, clinical development and regulatory affairs, positioning the company to navigate the complex requirements of orphan drug designation and clinical trial execution. With a focus on innovation and strategic alliances, Grace Therapeutics aims to deliver transformative treatments for patients affected by rare genetic disorders.

Key Stats

• Today's Range: $2.98 to $3.08
• 50-Day Range: $2.87 to $3.30
• 52-Week Range: $1.75 to $4.97
• Volume: 119,402 shs
• Average Volume: 65,395 shs
• Market Capitalization: $41.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Hold

Grace Therapeutics Stock Analysis - MarketRank™

Grace Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 540th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Grace Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Grace Therapeutics has a consensus price target of $12.00, representing about 301.3% upside from its current price of $2.99.

Amount of Analyst Coverage

Grace Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Grace Therapeutics are expected to grow in the coming year, from ($1.06) to ($0.75) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Grace Therapeutics is -3.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Grace Therapeutics is -3.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Grace Therapeutics has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.07% of the float of Grace Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Grace Therapeutics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Grace Therapeutics has recently increased by 60.17%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Grace Therapeutics does not currently pay a dividend.

Dividend Growth

Grace Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.07% of the float of Grace Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Grace Therapeutics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Grace Therapeutics has recently increased by 60.17%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.38

News Sentiment

Grace Therapeutics has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Grace Therapeutics this week, compared to 1 article on an average week.

MarketBeat Follows

Only 1 people have added Grace Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Grace Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.10% of the stock of Grace Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 6.08% of the stock of Grace Therapeutics is held by institutions.

GRCE Stock Analysis - Frequently Asked Questions

How have GRCE shares performed this year?

Grace Therapeutics' stock was trading at $3.74 on January 1st, 2025. Since then, GRCE shares have decreased by 20.1% and is now trading at $2.99.

How were Grace Therapeutics' earnings last quarter?

Grace Therapeutics, Inc. (NASDAQ:GRCE) posted its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.01.

How do I buy shares of Grace Therapeutics?

Shares of GRCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/12/2025
• Today: 10/10/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GRCE
• Previous Symbol: NASDAQ:GRCE
• CIK: 1444192
• Web: www.acastipharma.com
• Phone: 818-839-4378
• Fax: 45-0687-2272
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Grace Therapeutics: $12.00
• High Price Target: $12.00
• Low Price Target: $12.00
• Potential Upside/Downside: +301.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.57 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -20.36%
• Return on Assets: -18.09%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.87
• Quick Ratio: 8.87

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.86 per share
• Price / Book: 0.62

Miscellaneous

• Outstanding Shares: 13,829,000
• Free Float: 12,294,000
• Market Cap: $41.35 million
• Optionable: N/A
• Beta: 1.00